Liminatus Pharma, Inc.

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for cancer. The company’s current work centers on immune-modulating treatments designed to address solid tumors, with a particular emphasis on CD47-blockade technology and its candidate IBA101, a humanized anti-CD47 monoclonal antibody. Liminatus Pharma is also associated with broader oncology research efforts that explore next-generation immune-based approaches and CAR-T platforms for difficult-to-treat cancers. Its business is concentrated in the biotechnology and healthcare sectors, where it contributes to the development of targeted cancer therapies intended to expand treatment options in oncology. Founded in 2018 and headquartered in California, Liminatus Pharma remains focused on advancing clinical research and therapeutic development for patients with unmet needs in cancer care.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Chris Kim J.D., L.L.M.

Employees

1

Headquarters

Cerritos, CA, United States

Website

liminatuspharma.com